Abbott Laboratories (ABT) - What Are Researchers Thinking About This Stock?

Abbott Laboratories logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts are broadly bullish: Abbott has a “Moderate Buy” consensus among 27 brokerages, with an average 12-month price target of $119.04. Recent target changes were mixed, though Leerink upgraded the stock to “outperform” with a $124 target.
  • Quarterly results showed growth: Abbott matched consensus EPS at $1.42 and slightly exceeded revenue estimates with $13.01 billion; revenue rose 14.5% year over year.
  • Pipeline and income news: Abbott has begun a clinical trial of its investigational Encantor TAVI system, while its quarterly dividend of $0.63 per share equates to a 2.4% annualized yield.
  • MarketBeat previews the top five stocks to own by December 1st.

Shares of Abbott Laboratories (NYSE:ABT - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the twenty-seven brokerages that are currently covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation, twenty-two have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $119.04.

A number of research firms recently weighed in on ABT. Leerink Partners upgraded Abbott Laboratories from a "market perform" rating to an "outperform" rating and set a $124.00 price objective for the company in a report on Thursday. Royal Bank Of Canada lowered their price objective on Abbott Laboratories from $130.00 to $125.00 and set an "outperform" rating for the company in a research report on Thursday, October 22nd. Citigroup reduced their target price on Abbott Laboratories from $125.00 to $122.00 and set a "buy" rating on the stock in a report on Thursday, October 22nd. JPMorgan Chase & Co. dropped their price target on shares of Abbott Laboratories from $120.00 to $118.00 and set an "overweight" rating on the stock in a research report on Thursday, October 22nd. Finally, Argus cut shares of Abbott Laboratories from a "buy" rating to a "hold" rating in a research report on Tuesday, October 27th.

Read Our Latest Analysis on Abbott Laboratories

Abbott Laboratories Stock Down 0.4%

Shares of ABT opened at $104.03 on Friday. The firm has a market cap of $180.17 billion, a P/E ratio of 38.82, a price-to-earnings-growth ratio of 1.83 and a beta of 0.54. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.00 and a current ratio of 1.45. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $129.85. The firm's 50-day simple moving average is $103.89 and its 200 day simple moving average is $101.69.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 EPS for the quarter, hitting analysts' consensus estimates of $1.42. The business had revenue of $13.01 billion for the quarter, compared to analyst estimates of $12.99 billion. Abbott Laboratories had a net margin of 9.75% and a return on equity of 18.04%. Abbott Laboratories's revenue for the quarter was up 14.5% compared to the same quarter last year. During the same period last year, the firm earned $1.30 earnings per share. On average, analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, November 16th. Investors of record on Thursday, October 15th were issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date was Thursday, October 15th. Abbott Laboratories's dividend payout ratio is currently 94.03%.

Key Abbott Laboratories News

These are some of the ABT news items that stood out recently:

  • Positive Sentiment: Leerink Partners upgraded Abbott from “market perform” to “outperform” and set a $124 price target, signaling increased confidence in the company’s prospects. MedTech poised to outperform in 2027, Leerink says as Abbott upgraded
  • Positive Sentiment: Abbott began the VOYAGER CE trial of its investigational Encantor software-guided TAVI system for severe aortic stenosis. The technology is designed to help tailor valve deployment to a patient’s anatomy, potentially strengthening Abbott’s structural-heart pipeline; trial results will be needed to establish its safety and efficacy. Abbott initiates VOYAGER clinical trial
  • Positive Sentiment: A commentary highlighted Abbott’s 54 consecutive years of dividend growth and said a potential spin-off of its nutrition division could lead to a re-rating of the stock. The spin-off remains a prospective catalyst, not a confirmed outcome in the article. 3 Dividend Kings to Buy in November and Never Sell

Insider Activity

In related news, EVP Mary Moreland sold 3,500 shares of the firm's stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $116.00, for a total transaction of $406,000.00. Following the transaction, the executive vice president directly owned 100,791 shares of the company's stock, valued at $11,691,756. This trade represents a 3.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.46% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. PCM Encore LLC acquired a new stake in Abbott Laboratories during the 3rd quarter valued at $212,000. Defiance ETFs LLC boosted its stake in shares of Abbott Laboratories by 13.7% during the third quarter. Defiance ETFs LLC now owns 7,909 shares of the healthcare product maker's stock valued at $782,000 after acquiring an additional 954 shares during the last quarter. Tradewinds LLC. boosted its stake in shares of Abbott Laboratories by 909.7% during the third quarter. Tradewinds LLC. now owns 4,917 shares of the healthcare product maker's stock valued at $486,000 after acquiring an additional 4,430 shares during the last quarter. Advisors Asset Management Inc. purchased a new stake in Abbott Laboratories during the 3rd quarter worth about $3,220,000. Finally, DGS Capital Management LLC increased its position in Abbott Laboratories by 42.0% during the 3rd quarter. DGS Capital Management LLC now owns 6,614 shares of the healthcare product maker's stock worth $654,000 after purchasing an additional 1,957 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company's stock.

Abbott Laboratories Company Profile

(Get Free Report)

Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott's offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.

Further Reading

Analyst Recommendations for Abbott Laboratories (NYSE:ABT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Abbott Laboratories Right Now?

Before you consider Abbott Laboratories, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.

While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines